Response to Eribulin in a patient with metastatic uterine leiomyosarcoma: a case report
| Autor: | Francesco Tolomeo, Massimo Aglietta, Sandra Aliberti, Giovanni Grignani, Sara Miano, Alessandra Merlini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Leiomyosarcoma
Cancer Research medicine.medical_specialty Biopsy medicine.medical_treatment rare cancers Antineoplastic Agents novel chemotherapeutic agents Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Bone Marrow medicine Humans 030212 general & internal medicine Neoplasm Metastasis Furans eribulin Trabectedin Neoplasm Staging Chemotherapy Hysterectomy medicine.diagnostic_test business.industry General Medicine Ketones Middle Aged leiomyosarcoma medicine.disease Magnetic Resonance Imaging Gemcitabine Treatment Outcome Oncology chemistry 030220 oncology & carcinogenesis Female Radiology Tomography X-Ray Computed business Eribulin medicine.drug |
| Popis: | We report the case of a 51 year-old patient affected by an advanced uterine leiomyosarcoma treated with eribulin as fourth-line therapy. The patient, with a previous history of leiomyomas of the myometrium, had undergone total hysterectomy for repeated metrorrhagias. After 7 years, metastases in the liver, bone and lung were documented. A fine needle liver biopsy demonstrated leiomyosarcoma metastasis. The patient was treated with first-line doxorubicin chemotherapy; after six cycles, disease progression was observed. A second-line trabectedin chemotherapy and a third-line gemcitabine chemotherapy were performed; no objective responses were seen after two cycles. The patient was then treated with eribulin on the basis of an EORTC Phase II trial showing preliminary activity in uterine leiomyosarcoma. After six cycles, CT scan showed partial remission of liver lesion. Disease progression was observed after nine cycles with eribulin, without severe side effects and preserving a good quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|